Pregnancy-associated plasma protein-A (PAPPA) promotes breast cancer progression

References

• Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365(9472):1727–1741.
   PubMedGoogle Scholar
• DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409–418.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.
   PubMed Web of Science ®Google Scholar
• Peairs KS, Choi Y, Stewart RW, et al. Screening for breast cancer. Semin Oncol. 2017;44(1):60–72.
   PubMed Web of Science ®Google Scholar
• Braden AM, Stankowski RV, Engel JM, et al. Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des. 2014;20(30):4879–4898.
   PubMed Web of Science ®Google Scholar
• de la Mare JA, Contu L, Hunter MC, et al. Breast cancer: current developments in molecular approaches to diagnosis and treatment. Recent Pat Anticancer Drug Discov. 2014;9(2):153–175.
   PubMed Web of Science ®Google Scholar
• Miller L, Smith EC. Breast cancer prognostic tests: helping patients understand testing results and their implications. Clin J Oncol Nurs. 2019;23(5):478–481.
   PubMed Web of Science ®Google Scholar
• Khalil AI, Bendahhou K, Mestaghanmi H, et al. Cancer du sein au Maroc: profil phénotypique des tumeurs [Breast cancer in Morocco: phenotypic profile of tumors]. Pan Afr Med J. 2016;25:74.
   PubMedGoogle Scholar
• Vivanco M. Biomarkers in breast cancer. Methods Mol Biol. 2010;593:137–156.
   PubMedGoogle Scholar
• An SM, Evans AJ, Lam TP, et al. How relevant is breast cancer screening in the Asia/Pacific region? Breast. 2007;16(2):113–119.
   PubMed Web of Science ®Google Scholar
• Pinto R, De Summa S, Pilato B, et al. DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer. Curr Mol Med. 2014;14(1):45–57.
   PubMed Web of Science ®Google Scholar
• Li J, Shen L, Xiao XG, et al. MicroRNAs in breast cancer and breast cancer stem cells and their potential for breast cancer therapy. Chin Med J (Engl). 2013;126(13):2556–2563.
   PubMed Web of Science ®Google Scholar
• Keshtgar M, Davidson T, Pigott K, et al. Current status and advances in management of early breast cancer. Int J Surg. 2010;8(3):199–202.
   PubMed Web of Science ®Google Scholar
• Jin C, Gao S, Li D, et al. MiR-182-5p inhibits the proliferation of vascular smooth muscle cells induced by ox-ldl through targeting PAPPA. Int Heart J. 2020;61(4):822–830.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ma W, Bian H, et al. Long non-coding RNA MIAT/miR-148b/PAPPA axis modifies cell proliferation and migration in ox-LDL-induced human aorta vascular smooth muscle cells. Life Sci. 2020;256:117852.
   PubMed Web of Science ®Google Scholar
• Conover CA, Oxvig C. PAPP-A and cancer. J Mol Endocrinol. 2018;61(1):T1–T10.
   PubMed Web of Science ®Google Scholar
• Yliniemi A, Makikallio K, Korpimaki T, et al. Combination of PAPPA, fhCGβ, AFP, PlGF, sTNFR1, and maternal characteristics in prediction of early-onset preeclampsia. 2015;Clin Med Insights Reprod Health. 9:13–20.
   PubMed Web of Science ®Google Scholar
• Lu G, Chu Y, Tian P. Knockdown of H19 attenuates Ox-LDL-induced vascular smooth muscle cell proliferation, migration, and invasion by regulating miR-599/PAPPA axis. J Cardiovasc Pharmacol. 2021;77(3):386–396.
   PubMed Web of Science ®Google Scholar
• Guo Y, Bao Y, Guo D, et al. Pregnancy-associated plasma protein a in cancer: expression, oncogenic functions and regulation. Am J Cancer Res. 2018;8(6):955–963.
   PubMed Web of Science ®Google Scholar
• Heitzeneder S, Sotillo E, Shern JF, et al. Pregnancy-associated plasma protein-A (PAPP-A) in ewing sarcoma: role in tumor growth and immune evasion. J Natl Cancer Inst. 2019;111(9):970–982.
   PubMedGoogle Scholar
• Loddo M, Andryszkiewicz J, Rodriguez-Acebes S, et al. Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. J Pathol. 2014;233(4):344–356.
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Traina TA, King TA. Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. Surg Oncol Clin N Am. 2013;22(4):823–840.
   PubMed Web of Science ®Google Scholar
• Dodiyi-Manuel A, Wakama IE. Predispositions of carcinoma of the breast: a review. Niger J Med. 2014;23(1):7–12.
   PubMedGoogle Scholar
• He YS, Peng YL, Yang H, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(1):30–34.
   PubMedGoogle Scholar
• Lerebours F. Traitements néoadjuvants du cancer du sein: marqueurs géno- et phénotypiques de la réponse thérapeutique et du pronostic [primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]. Pathol Biol (Paris). 2006;54(4):209–214
   PubMedGoogle Scholar
• Arciero C, Somiari SB, Shriver CD, et al. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers. 2003;18(4):241–272.
   PubMed Web of Science ®Google Scholar
• Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005;26(6):281–293.
   PubMedGoogle Scholar
• Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 2002;44(2):121–141.
   PubMed Web of Science ®Google Scholar
• Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol. 2009;19(4):204–210.
   PubMed Web of Science ®Google Scholar
• Shen Y, Peng X, Shen C. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112(3):2640–2646.
   PubMed Web of Science ®Google Scholar
• Gonçalves A, Viens P, Sobol H, et al. Altérations moléculaires des cancers du sein: applications cliniques et nouveaux outils d’analyse [Molecular alterations in breast cancer: clinical implications and new analytical tools]. Rev Med Interne. 2005;26(6):470–478.
   PubMed Web of Science ®Google Scholar
• Consuegra-Sanchez L, Fredericks S, Kaski JC. Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis. 2009;203(2):346–352.
   PubMed Web of Science ®Google Scholar
• Huang J, Tabata S, Kakiuchi S, et al. Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target. Oncotarget. 2013;4(8):1172–1184.
   PubMedGoogle Scholar
• Boldt HB, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007;17(1):10–18.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Visscher DW, Hart SN, et al. Pregnancy-associated plasma protein-A expression in human breast cancer. Growth Horm IGF Res. 2014;24(6):264–267.
   PubMed Web of Science ®Google Scholar
• Bulut I, Coskun A, Ciftci A, et al. Relationship between pregnancy-associated plasma protein-A and lung cancer. Am J Med Sci. 2009;337(4):241–244.
   PubMed Web of Science ®Google Scholar
• Nakasato M, Kohsaka H, Mizutani T, et al. Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation. Endocrine. 2013;43(2):387–393.
   PubMed Web of Science ®Google Scholar
• Boldt HB, Glerup S, Overgaard MT, et al. Definition, expression, and characterization of a protein domain in the N-terminus of pregnancy-associated plasma protein-A distantly related to the family of laminin G-like modules. Protein Expr Purif. 2006;48(2):261–273.
   PubMed Web of Science ®Google Scholar